Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

TLR3 stimulation improves the migratory potency of adipose-derived mesenchymal stem cells through the stress response pathway in the melanoma mouse model.

Eskandari F., Zolfaghari S., Yazdanpanah A., Shabestari RM., Fomeshi MR., Milan PB.

Animal Study with a reported sample of 5 on Chronic Inflammation, published in Mol Biol Rep (2022) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Mol Biol Rep (2022)
Country
Netherlands
Reported sample size
5
Source database
PubMed
PMID
36575321
DOI
10.1007/s11033-022-08111-8
Citations
3

Abstract (original English)

Background: Mesenchymal stem cells (MSCs) are utilized as a carrier of anti-tumor agents in targeted anti-cancer therapy. Despite the improvements in this area, there are still some unsolved issues in determining the appropriate dose, method of administration, biodistribution, and long-term survival. The current study aimed to determine the influence of toll-like receptor 3 (TLR3) stimulation on the potential of MSCs migration to the neoplasm environment in the mouse melanoma model. Methods and Results Adipose-derived MSCs (ADMSCs) were isolated from the GFP + transgenic C57BL/6 mouse and treated with different doses (1µg/ml and 10 µg/ml) of polyinosinic-polycytidylic acid [poly(I:C)], the related TLR3 agonist, at various time points (1 and 4 hours). Following the treatment, the expression pattern of targeted genes such as α4, α5, and β1 integrins and TGF-β and IL-10 anti-inflammatory cytokines was determined using real-time PCR. In vivo live imaging evaluated the migration index of the intraperitoneally (IP) injected treated ADMSCs in a lung tumor-bearing mouse (C57BL/6) melanoma model (n = 5). The presented findings demonstrated that TLR3 stimulation led to enhanced migration of ADMSCs to the tumor area compared with control group (n = 5) and enhanced expression of α4, α5, and β1 integrins. It was also detected that the engagement of TLR3 resulted in the anti-inflammatory beh

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
MiceAnimalsToll-Like Receptor 3Tissue DistributionMice, Inbred C57BLMesenchymal Stem CellsDisease Models, AnimalMelanomaIntegrins

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research